Evidence map›Paper›PMID 35435462›Full record

ArticlePsychopharmacology2022

Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses.

Laísa S Umpierrez, Priscila A Costa, Eden A Michelutti, Sarah J Baracz, Melanie Sauer, Anita J Turner, Nicholas A Everett, Jonathon C Arnold, Iain S McGregor, Jennifer L Cornish

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Cannabidiol alleviates methamphetamine addictionActa pharmaceutica Sinica. B · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Laísa S Umpierrez *Department of Psychology, Macquarie University, North Ryde, NSW, Australia.
Priscila A Costa *Department of Psychology, Macquarie University, North Ryde, NSW, Australia.
Eden A MicheluttiDepartment of Psychology, Macquarie University, North Ryde, NSW, Australia.
Sarah J BaraczDepartment of Psychology, Macquarie University, North Ryde, NSW, Australia.
Melanie SauerDepartment of Psychology, Macquarie University, North Ryde, NSW, Australia.
Anita J TurnerDepartment of Psychology, Macquarie University, North Ryde, NSW, Australia.
Nicholas A EverettDepartment of Psychology, Macquarie University, North Ryde, NSW, Australia.
Jonathon C ArnoldLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, NSW, Australia.
Iain S McGregorLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, NSW, Australia.
Jennifer L CornishDepartment of Psychology, Macquarie University, North Ryde, NSW, Australia. jennifer.cornish@mq.edu.au.ORCID http://orcid.org/0000-0002-9754-8069
Macquarie University · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCannabidiol (CBD) and cannabidiolic acid (CBDA) are non-psychoactive components of the cannabis plant. CBD has been well characterised to have anxiolytic and anticonvulsant activity, whereas the behavioural effects of CBDA are less clear. Preclinical and clinical data suggests that CBD has antipsychotic properties and reduces methamphetamine self-administration in rats. An animal model that is commonly used to mimic the neurochemical changes underlying psychosis and drug dependence is methamphetamine (METH) sensitisation, where repeated administration of the psychostimulant progressively increases the locomotor effects of METH.

objectiveThe aim of this study was to determine whether CBD or CBDA attenuate METH-induced sensitisation of locomotor hyperactivity in rats.

methodsEighty-six male Sprague Dawley rats underwent METH sensitisation protocol where they were subjected to daily METH (1 mg/kg on days 2 and 8, 5 mg/kg on days 3-7; i.p.) injections for 7 days. After 21 days of withdrawal, rats were given a prior injection of CBD (0, 40 and 80 mg/kg; i.p.) or CBDA (0, 0.1, 10 and 1000 µg/kg; i.p.) and challenged with acute METH (1 mg/kg; i.p.). Locomotor activity was then measured for 60 min.

resultsRats displayed robust METH sensitisation as evidenced by increased locomotor activity to METH challenge in METH-pretreated versus SAL-pretreated rats. CBD (40 and 80 mg/kg) reduced METH-induced sensitisation. There was no effect of any CBDA doses on METH sensitisation or acute METH-induced hyperactivity.

conclusionThese results demonstrate that CBD, but not CBDA, reduces METH sensitisation of locomotor activity in rats at pharmacologically effective doses, thus reinforcing evidence that CBD has anti-addiction and antipsychotic properties.

Indexed as

Antipsychotic AgentsCannabidiolMethamphetamineAnimalsCannabinoidsMaleRatsRats, Sprague-DawleyAntipsychotic AgentsCannabidiolcannabidiolic acidCannabinoidsMethamphetamineCannabidiolCannabidiolic acidLocomotor activityMethamphetaminePsychosisSensitisation

Identifiers

PMID35435462
PMCPMC9110442
OpenAlexW4223923931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.